Hyaluronic acid-quercetin conjugate micelles: Synthesis, characterization, in vitro and in vivo evaluation

Colloids and Surfaces B: Biointerfaces

Volumn 123, Issue , 2014, Pages 778-786

  Pang, Xin ^a   Lu, Zhen ^b   Du, Hongliang ^a   Yang, Xiaoye ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b Department of Pharmacy Taian Rongjun Hospital of Shandong Province   (China)

Author keywords

CD44; Hyaluronic acid; Polymer drug conjugates; Quercetin; Tumor targeting

Indexed keywords

CELL CULTURE; CELLS; DRUG DELIVERY; DRUG PRODUCTS; FLAVONOIDS; MICELLES; ORGANIC ACIDS; PHENOLS; POLYMERS; TUMORS;

AVERAGE DIAMETER; CD44; DRUG-CONJUGATES; INHIBITION EFFECT; INHIBITORY ACTIVITY; POLYMERIC CARRIERS; QUERCETIN; TUMOR TARGETING;

HYALURONIC ACID;

HYALURONIC ACID; QUERCETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER CELL CARCINOMA; MEAN RESIDENCE TIME; MICELLE; MICROMORPHOLOGY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR GROWTH;

EID: 84915781472     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.10.025     Document Type: Article

References (35)

1. Borghetti G., Carini J., Honorato S., Ayala A., Moreira J., Bassani V. Physicochemical properties and thermal stability of quercetin hydrates in the solid state. Thermochim. Acta 2012, 539:109.
2. Chen X., Yin O.Q., Zuo Z., Chow M.S. Pharmacokinetics and modeling of quercetin and metabolites. Pharm. Res. 2005, 22:892.
3. Duo J., Ying G.-G., Wang G.-W., Zhang L. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Mol. Med. Report. 2012, 5:1453.
4. Youn H., Jeong J.-C., Jeong Y.S., Kim E.-J., Um S.-J. Quercetin potentiates apoptosis by inhibiting nuclear factor-kappa B signaling in H460 lung cancer cells. Biol. Pharm. Bull. 2012, 36:944.
5. Zheng S.-Y., Li Y., Jiang D., Zhao J., Ge J.-F. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A549. Mol. Med. Report. 2012, 5:822.
6. Vidya Priyadarsini R., Senthil Murugan R., Maitreyi S., Ramalingam K., Karunagaran D., Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur. J. Pharmacol. 2010, 649:84.
7. Cai X., Fang Z., Dou J., Yu A., Zhai G. Bioavailability of quercetin: Problems and promises. Curr. Med. Chem. 2013, 20:2572.
8. Pang X., Du H.-L., Zhang H.-Q., Zhai Y.-J., Zhai G.-X. Polymer-drug conjugates: Present state of play and future perspectives. Drug Discov. Today 2013, 18:1316.
9. Fraser J., Laurent T., Laurent U. Hyaluronan: Its nature, distribution, functions and turnover. J. Intern. Med. 1997, 242:27.
10. Noble P.W., Liang J., Jiang D. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011, 91:221.
11. Teh B.M., Shen Y., Friedland P.L., Atlas M.D., Marano R.J. A review on the use of hyaluronic acid in tympanic membrane wound healing. Expert Opin. Biol. Ther. 2012, 12:23.
12. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., Ghatak S. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011, 278:1429.
13. Oh E.J., Park K., Kim K.S., Kim J., Yang J.-A., Kong J.-H., Lee M.Y., Hoffman A.S., Hahn S.K. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J. Control. Rel. 2010, 141:2.
14. Goodarzi N., Varshochian R., Kamalinia G., Atyabi F., Dinarvand R. A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr. Polym. 2013, 92:1280.
15. Luo Y., Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconj. Chem. 1999, 10:755.
16. Duncan R. Development of hpma copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv. Drug Del. Rev. 2009, 61:1131.
17. Ogura H., Nagai S., Takeda K. A novel reagent (N-succinimidyl diphenylphosphate) for synthesis of active ester and peptide. Tetrahedron Lett. 1980, 21:1467.
18. Xin D., Wang Y., Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: Synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm. Res. 2010, 27:380.
19. Wang Y., Xin D., Liu K., Xiang J. Heparin-paclitaxel conjugates using mixed anhydride as intermediate: Synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. Pharm. Res. 2009, 26:785.
20. Song S., Chen F., Qi H., Li F., Xin T., Xu J., Ye T., Sheng N., Yang X., Pan W. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel. Pharm. Res. 2014, 31:1032.
21. Zheng W., Li Y., Du J., Yin Z. Fabrication of biocompatible and tumor-targeting hyaluronan nanospheres by a modified desolvation method. J. Pharm. Sci. 2014, 103:1529.
22. Jain A., Agarwal A., Majumder S., Lariya N., Khaya A., Agrawal H., Majumdar S., Agrawal G.P. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J. Control. Rel. 2010, 148:359.
23. Jamshidzadeh A., Mehrabadi A.R. Protective effect of quercetin on oxidative stress in glucose-6-phosphate dehydrogenase-deficient erythrocytes in vitro. Iran. J. Pharm. Res. 2010, 9:169.
24. Serrano D.R., Hernández L., Fleire L., González-Alvarez I., Montoya A., Ballesteros M.P., Dea-Ayuela M.A., Miró G., Bolás-Fernández F., Torrado J.J. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. Int. J. Pharm. 2013, 447:38.
25. Lovell M., Johnson H., Hui H.-W., Cannon J., Gupta P., Hsu C. Less-painful emulsion formulations for intravenous administration of clarithromycin. Int. J. Pharm. 1994, 109:45.
26. Lu Y., Wang Y., Tang X. Formulation and thermal sterile stability of a less painful intravenous clarithromycin emulsion containing vitamin E. Int. J. Pharm. 2008, 346:47.
27. Boucenna I., Royon L., Colinart P., Guedeau-Boudeville M.-A., Mourchid A. Structure and thermorheology of concentrated pluronic copolymer micelles in the presence of Laponite particles. Langmuir 2010, 26:14430.
28. Cheng R., Wang X., Chen W., Meng F., Deng C., Liu H., Zhong Z. Biodegradable poly (e{open}-caprolactone)-g-poly (2-hydroxyethyl methacrylate) graft copolymer micelles as superior nano-carriers for "smart" doxorubicin release. J. Mater. Chem. 2012, 22:11730.
29. Ponta A., Bae Y. PEG-poly (amino acid) block copolymer micelles for tunable drug release. Pharm. Res. 2010, 27:2330.
30. Yousefpour P., Atyabi F., Vasheghani-Farahani E., Movahedi A., Dinarvand R. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int. J. Nanomed. 2011, 6:1977.
31. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657.
32. Seymour L., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 1995, 31:766.
33. Kelava T., Ćavar I., Čulo F. Biological actions of drug solvents. Period. Biol. 2011, 113:311.
34. Kleemann R., Verschuren L., Morrison M., Zadelaar S., van Erk M.J., Wielinga P.Y., Kooistra T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011, 218:44.
35. Boots A.W., Wilms L.C., Swennen E.L., Kleinjans J., Bast A., Haenen G.R. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 2008, 24:703.